Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
CRSP Stock Chart & Stats
$51.58
-$0.92(-2.19%)
At close: 4:00 PM EST
$51.58
-$0.92(-2.19%)
Day’s Range― - ―
52-Week Range$30.04 - $78.48
Previous CloseN/A
Volume437.82K
Average Volume (3M)2.38M
Market Cap
$4.97B
Enterprise Value$4.21B
Total Cash (Recent Filing)$1.92B
Total Debt (Recent Filing)$211.02M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Feb 17, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding95,300,230
10 Day Avg. Volume2,208,830
30 Day Avg. Volume2,375,761
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.72
Price to Sales (P/S)94.87
P/FCF Ratio-22.95
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue114.53
Enterprise Value/Gross Profit-32.23
Enterprise Value/Ebitda-7.95
Forecast
1Y Price Target
$70.33Price Target Upside36.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)-6.22
Revenue Forecast (FY)$7.84M
Bulls Say, Bears Say
Bulls Say
CASGEVY Revenue GrowthCASGEVY momentum is building, with metrics, the funnel, and first guidance pointing to a more visible revenue ramp in 2026.
Financial PerformanceReinforced balance sheet supports multi-asset execution, with cash increased from $1.72B to $1.94B.
Product InnovationCTX310 offers a comprehensive treatment for severe dyslipidemia that may replace lifelong drugs with a one-time solution.
Bears Say
Profitability ConcernsCasgevy's costs continue to significantly outpace sales, making it unlikely CRISPR will report profit in the near term.
Program DeprioritizationThe most notable update out of the print was the deprioritization of CD70 CAR-T/’131 oncology program.
Stock RisksRisks to the stock rating and price target include clinical execution risks, regulatory risks, and competitive dynamics.
Crispr Therapeutics AG News
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $30.04 and its highest was $78.48 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Crispr Therapeutics AG’s market cap is $4.97B.
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Feb 17, 2026 which is in 75 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Nov 10, 2025. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.265 by $0.095.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -1.18.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 95,300,230 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.265. Following the earnings report the stock price went down -0.98%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Currently, no hedge funds are holding shares in CRSP
Crispr Therapeutics AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.33 (36.35% Upside)
$70.33 (36.35% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 73%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 737.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.95%
12-Months-Change
Fundamentals
Return on Equity
-25.33%
Trailing 12-Months
Asset Growth
-0.48%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
Crispr Therapeutics AG is a biotechnology company based in Switzerland that focuses on developing transformative gene-based medicines for serious diseases. Utilizing its proprietary CRISPR/Cas9 gene-editing technology, the company aims to create innovative therapies for a range of conditions, including genetic disorders, cancer, and diabetes. Crispr Therapeutics operates primarily in the healthcare sector, with a robust pipeline of product candidates that includes both in vivo and ex vivo applications, as well as collaborations with other biopharmaceutical companies to advance its therapeutic offerings.
CRSP Stock 12 Month Forecast
Average Price Target
$70.33
▲(36.35% Upside)
Technical Analysis
Intellia Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
Verve Therapeutics
―
Ownership Overview
2.66% Insiders
14.77% Mutual Funds
19.57% Other Institutional Investors
43.47% Public Companies and Individual Investors